A letter on the June 2021 issue of Pharm Exec from Chairman and Founder of MJH Life Sciences, Mike Hennessy Sr.
It’s an embarrassment of riches, really, what Pharmaceutical Executive brings to the table this month. Not only do we list the Top 50 Pharmaceutical Companies by 2020 revenue, we also feature leaders from the pharmaceutical companies responsible for the life-saving science that became the vaccines and treatments to fight COVID-19. If that weren’t enough, our Executive Profile of Michelle McMurry-Heath, MD, PhD, President and CEO of BIO, ties together the need of the biopharma ecosystem to continue its strong collaborations to support scientific innovation, as well as invest in diversity and practices that will help stem systemic inequities within global healthcare. We commend the biopharma industry for its scientific success in bringing therapeutics to the world. And we commend all of the doctors and nurses who worked tirelessly for their patients during this pandemic.
Now that we’ve reached a tipping point in the COVID-19 crisis in the US and more Americans are getting vaccinated, it appears life is returning to normal. To prepare for the return to the workplace, Elaine Quilici, Senior Editor of Pharmaceutical Executive, writes in her Leadership column: “A PwC article about returning to the office after COVID [states]: ‘Management teams should lead with empathy and demonstrate an understanding that while all of their employees have experienced this crisis, they haven’t all experienced it the same way.’ There needs to be a sensitivity to individual situations and patience for allowing workers to adapt to new ways of working.”
As we continue to bring our high-quality media products to the pharmaceutical and healthcare industries, please know that we support you and your employees as we travel down this road to normalcy together.
Mike Hennessy Sr., Chairman and Founder of MJH Life Sciences
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.